{"id":553682,"date":"2026-04-27T09:46:06","date_gmt":"2026-04-27T07:46:06","guid":{"rendered":"https:\/\/medizinonline.com\/?p=553682"},"modified":"2026-04-27T09:55:47","modified_gmt":"2026-04-27T07:55:47","slug":"mirdametinib-obtient-lautorisation-pour-les-enfants-et-les-adultes-atteints-de-nf1","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/mirdametinib-obtient-lautorisation-pour-les-enfants-et-les-adultes-atteints-de-nf1\/","title":{"rendered":"Mirdam\u00e9tinib obtient l\u2019autorisation pour les enfants et les adultes atteints de NF1"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Depuis le 9&nbsp;avril&nbsp;2026, mirdam\u00e9tinib est disponible en Suisse pour le traitement des neurofibromes plexiformes symptomatiques inop\u00e9rables chez les adultes et les enfants (\u00e0 partir de 2&nbsp;ans) atteints de neurofibromatose de type&nbsp;1 (NF1) <\/strong><strong>[1, 2]<\/strong><strong>. Cette autorisation repose sur l\u2019\u00e9tude&nbsp;ReNeu, qui a enregistr\u00e9 <\/strong><strong>des taux de r\u00e9ponse importants et durables ainsi qu\u2019une am\u00e9lioration pr\u00e9coce, durable et cliniquement significative des douleurs et de la qualit\u00e9 de vie (QdV) <\/strong><strong>[3]<\/strong><strong>. Cela a \u00e9galement \u00e9t\u00e9 confirm\u00e9 par les donn\u00e9es du suivi \u00e0 long terme (LTFU) <\/strong><strong>[4]<\/strong><strong>.<\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmirdametinib-obtient-lautorisation-pour-les-enfants-et-les-adultes-atteints-de-nf1%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Depuis le 9&nbsp;avril&nbsp;2026, mirdam\u00e9tinib est disponible en Suisse pour le traitement des neurofibromes plexiformes symptomatiques inop\u00e9rables chez les adultes et les enfants (\u00e0 partir de 2&nbsp;ans) atteints de neurofibromatose de&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmirdametinib-obtient-lautorisation-pour-les-enfants-et-les-adultes-atteints-de-nf1%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":17461,"featured_media":553693,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Contenu sponsoris\u00e9: Neurofibromatose de type 1 (NF1)","footnotes":""},"category":[11345,11417,11417,11467,11383,11389,11389,11458,11345,11458,11464,11464,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-553682","post","type-post","status-publish","format-standard","has-post-thumbnail","category-contenu-des-partenaires","category-genetique","category-medecine-pharmaceutique","category-neurologie-fr","category-oncologie","category-pediatrie","category-pharmacologie-et-toxicologie","category-rx-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-04 08:14:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/17461"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=553682"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553682\/revisions"}],"predecessor-version":[{"id":555180,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/553682\/revisions\/555180"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/553693"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=553682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=553682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=553682"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=553682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}